COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical...

40
COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology

Transcript of COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical...

Page 1: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

COLORECTAL CANCER

Ozlem Uysal-Sonmez, MDYeditepe University Hospital

Department of Medical Oncology

Page 2: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Anatomy of the Colon andRectum

• The colon + rectum = the large intestine

• Colon makes upto first 150-180 cm of large intestine

• Rectum makes up the last 12-15cm ending at the anus

Page 3: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

The Colorectum

Page 4: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.
Page 5: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.
Page 6: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Epidemiology

• Third most common cancer

• Second most common cause of cancer death

• Male = Female

• Lifetime probability of 6% (1 in 17)

• Very curable if detected in early stages

Page 7: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Epidemiology

• Males=Females• Risk increases with age

– Average age at diagnosis is 67-70 yrs

• Highest in industrialized nations:– Canada, US, N/W Europe

• Most cancers start as polyps -precancerous growths that develop on the inner wall of the colon and rectum

Page 8: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Most of the colon and Rectumcancers are diagnosed at:

1) Routine physical to evaluate anemia

2) Screening colonoscopy

recommended for age 50 and over

Page 9: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

How Does Colorectal Cancer Develop?

Janne PA, Mayer RJ. N Engl J Med 2000;342:1960.

10 years

Page 10: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Etiology• Polyps (adenomatous)• Diet

• High-calorie, high-fat Western diet

• Inflammatory bowel disease• Ulcerative collitis

– Risk varies directly with extent of colonic involvement and duration of active disease

– Cumulative risk: 2% at 10 years, 8% at 20 years, 18% at 30 years

– Screening: Annual or semiannual colonoscopy in disease >8 years duration

• Crohn’s disease– Risk increased 1.5-2 folds

Page 11: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Etiology

• Genetic factors– Family history: depends on age of onset and number

of relatives• One 1st degree relative with CRC - 2 to 3 x risk• Two 1st degree relative with CRC -3 to 4 x risk• 1st degree relative < 50 years - 4 to 6 x risk• One 2nd degree relative with CRC- 1.5 x risk• One 1st degree relative with polyp - 2 x risk

– Hereditary syndromes (gene changes)• Familial adenomatosis poli• HNPCC (Hereditary nonpoliposis colorectal cancer)

Page 12: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Etiology

• Smoking

• Other factors• Personal or family history of other cancers (breast,

endometrium, ovary)• Exposure to asbestos (risk 1-2x)

Page 13: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Risk factors for Colorectal Cancer

Sporadic/ Sporadic/ Average Risk Average Risk 75%75%

Family History 15-20%

HNPCC 5% FAP-1%

IBD-1%

Page 14: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Risk groups for screening• Average risk

– Age ≥ 50 y– No inflammatoy bowel disease– No history of adenoma or colorectal cancer– Negative family history

• Increased risk– Personal history of

• Adenoma/sessile serrated polyp• Inflammatoy bowel disease• Colorectal cancer

– Positive family history

• High risk syndromes– Lynch syndrome/Hereditary nonpolyposis colorectal cancer (HNPCC)– Polyposis syndromes (familial adenomatous polyposis, Peutz-

Jeggers syndrome, Juvenile polyposis syndrome, hyperplastic polyposis syndrome)

Page 15: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Screening tests for colorectal cancerAverage risk

Starts at age 50

1. Colonoscopy every 10 years • preferred if available• For every 1% increase in complete colonoscopy rate, the hazard of

death decreased by 3%.

2. Annual FOBT+Flexible sigmoidoscopy every 5 years

Annual Fecal occult blood test (FOBT)• Testing of stool for occult blood to detect colorectal cancer at an early

stage• Variation is observed in estimates of the sensitivity but its lower cost and

increased specificity to detect right-isded colonic lesions make it a good screening test

Flexible sigmoidoscopy every 5 years • In contrast to FOBT, has a high sensitivity and specificity • Involves the use of a 60 cm flexible sigmoidoscope• Detects left sided lesions

Page 16: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Screening

• Average risk– Colonoscopy every 10 yrs– Annual fecal occult blood test (FOBT) + Flex

sigmoidoscopy every 5 years– Double contrast barium every 5-10 yrs

• High-Risk – Depends on risk

Page 17: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Who is High Risk?

• Familial Polyposis (APC Mutation)– Sigmoidoscopy in teenage years– Colectomy

• HNPCC (Mismatch Repair Genes)– Colonoscopy in 20’s

• Family History: – Colonoscopy 10 years younger than

index family case

Page 18: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Screening Strategies

Colonoscopy

• FOBT+ Flex Sig.• Virtual

Colonoscopy

One-Stage Screening Two-Stage Screening

Colonoscopy

Page 19: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Prevention

• Periodic sigmoidoscopy+FOB or colonoscopy

• Diet

• NSAID: Sulindac, aspirin

Page 20: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Pathology and natural history

• Pathology– Adenocarcinoma is most common type– Cancers of anal verge: Most often squamous cell or basaloid

carcinomas

• Most arise from adenomatous polyps

Page 21: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Site Distribution

Page 22: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Pathology and natural history

• Proximal tumors– More genetically unstable– May arise through same mechanisms

underlying HNPCC

• Distal tumors– greater genetic stability– May develop through same mechanisms

underlying polyposis-associated colorectal cancer

Page 23: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Natural history

• Tumors spread through the walls of the intestine and into the lymphatic system

• Metastases to lymph nodes in 40%-70%

• Tumors most commonly spread to the liver because venous blood flow from the colorectal tumor is through the portal vein

• Most common: Liver, peritoneal cavity, lung• Rectum cancers are 3 times more likely to recur locally,

because most of rectum lacks serosal layer• Because of venous and lymphatic drainage of rectum to

inferior vena cava, rectum cancers often recur first in lung

Page 24: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Clinical Manifestations

• Many colorectal cancers cause no symptoms in the early stages.

• Goal of screening is to detect cancers in the early stages, before symptoms develop.

• Symptoms in the later stages include:– Change in bowel habits– Blood in stool– Fatigue– Loss of appetite– Abdominal pain– Nausea– Weight loss– Anemia.

Page 25: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Clinical Manifestations

• Cancer on the right side gives rise to manifestations that are different from those on the left side of the colon

• Left-sided lesions• Rectal bleeding• Alternating constipation and diarrhea• Narrow, ribbonlike stools

• Right-sided lesions• Usually asymptomatic• Vague abdominal discomfort• Iron deficiency anemia• Occult bleeding

Page 26: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Diagnosis & Staging

• General evaluation– History, Physical examination with digital rectal

examination– CBC, liver function tests– Chest x-ray

• Carcinoembryonic antigen (CEA) screening• Colonoscopy or sigmoidoscopy or barium enema• Imaging tests

– CT scan or MRI– Ultrasound, Endorectal ultrasonography

Page 27: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.
Page 28: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.
Page 29: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Colon Polyp

Page 30: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Colon Cancer

Page 31: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Staging

• Stage I- Invades into muscle layer, but not into subserosa

• Stage II- Invades into subserosa, other organs, or associated with perforation, no nodal involvement

• Stage III- Lymph Node involvement

• Stage IV- Distant spread to other organs (liver, lungs)

Page 32: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Layers of the Colon Wall

Page 33: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.
Page 34: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Prognostic factors

• Stage

• Histological grade

• Clinical presentation• Perforation, obstruction worse

• High serum CEA level prior to surgery

Page 35: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Prognosis• Stage is the most powerful predictor of prognosis.

• Five-year relative survival by stageStage I >90%

Stage IIA 70-85%Stage IIB 55-65%

Stage IIIA 45-55%Stage IIIB 35-45%Stage IIIC 25-35%

Stage IV 8%

Page 36: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Treatment

• Treatment of colorectal cancer is one of the most rapidly changing and advancing areas in cancer research.

• Surgery is the mainstay of therapy

• Adjuvant chemotherapy– Large cancers or cancer that has spread to lymph nodes may

have left behind few scattered cancer cells in the body, even though no remaining cancer is detectable.

– Chemotherapy, 5-FU-based, may be recommended.– Stage III patients benefit most from chemotherapy after surgery.– Some Stage II patients may also benefit.– Usually given for 6 months.

• Radiation:– Has a major role in rectal cancer– Given either before surgery, or after surgery

Page 37: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Treatment

• Stage I-III: Goal is cure– Surgery – Adjuvant chemotehrapy: Stage III, some stage II

• 5-Fluorouracil based• Oxaliplatin

– Adjuvant radiotherapy: Rectal cancers

Page 38: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Treatment

• Stage IV: – Goals of therapy: palliation

• To improve cancer-related symptoms• To control cancers by delaying further growth and

spread• To shrink cancers• To improve survival (ie. to live longer with cancer)

– Chemotherapy: not curative– Palliative surgery and radiotherapy

Page 39: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Chemotherapy

• 5-Fluorouracil based

• Chemotherapeutics: Irinotecan, oxaliplatin

• Targetted agents– Anti VEGF antibody: Bevacizumab– Anti-EGFR antibody: Cetuximab

Page 40: COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.

Summary

• Early detection is crucial

• The development of new drugs and new drug combinations will continue to improve the outcome for cancer patients.